PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-24.71%
Negative net income growth while Biotechnology median is -7.72%. Seth Klarman would suspect a firm-specific problem if peers maintain profit growth.
3.01%
D&A growth of 3.01% while Biotechnology median is zero at 0.00%. Walter Schloss would question intangible or new expansions driving that cost difference.
No Data
No Data available this quarter, please select a different quarter.
9.00%
SBC growth of 9.00% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or staff additions causing more equity grants.
715.46%
Working capital of 715.46% while Biotechnology median is zero at 0.00%. Walter Schloss would check if expansions or cost inefficiencies cause that difference.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
244.38%
AP growth of 244.38% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or credit policies affecting the difference.
304.81%
Growth of 304.81% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or unusual one-time factors behind the difference.
412.12%
Growth of 412.12% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or one-off revaluations explaining the difference.
9.59%
Positive CFO growth while Biotechnology median is negative at -0.38%. Peter Lynch would see a notable cash advantage in a challenging sector environment.
100.00%
CapEx growth of 100.00% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or upgrades behind the difference.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Investing flow of 100.00% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or deals prompting that difference.
-4.76%
Debt repayment yoy declines while Biotechnology median is 0.00%. Seth Klarman fears increased leverage if expansions do not yield quick returns.
-85.80%
We reduce issuance yoy while Biotechnology median is 0.00%. Seth Klarman might see an advantage in preserving per-share value unless expansions are neglected.
No Data
No Data available this quarter, please select a different quarter.